Neferine sensitizes oral squamous cell carcinoma to cisplatin by disrupting the CCDC43-PNKP interaction

i

This article has been updated. A Correction to this article was published on .

i

The Original Article was published on

i

The Original Article was published on

i

This article has been updated

i

This article was retracted on

i

This article has been updated

Abstract

Oral squamous cell carcinoma (OSCC) poses a significant global health challenge due to its high recurrence rate and resistance to cisplatin. While DNA repair pathways contribute to chemoresistance, the role of scaffold proteins in stabilizing repair enzymes remains largely unexplored. This study aimed to elucidate the function of CCDC43 in cisplatin sensitivity and to identify a natural product targeting the CCDC43-PNKP axis. Bioinformatic analyses were conducted using bulk and single-cell transcriptomic and proteomic datasets. Molecular assays investigated the CCDC43-PNKP interaction and the impact of neferine on this axis. Xenograft models assessed the efficacy of combined neferine and cisplatin treatment. Machine learning identified CCDC43 as a key prognostic marker and driver of cisplatin resistance. CCDC43 was upregulated in OSCC epithelial cells and associated with poor survival. CCDC43 bound and stabilized PNKP by inhibiting ubiquitin-dependent degradation, thereby enhancing DNA repair and reducing cisplatin sensitivity. Through artificial intelligence-based virtual screening and experimental validation, neferine was found to disrupt the CCDC43-PNKP interaction, promoted PNKP degradation, increased cisplatin-induced DNA damage, and suppressed OSCC growth without acute toxicity. Collectively, the CCDC43-PNKP axis represents a critical therapeutic target in OSCC. Neferine is a promising ethnopharmacological agent capable of improving cisplatin sensitivity by targeting this pathway.

Keywords

Neferine / CCDC43 / PNKP / Oral cancer / Chemosensitivity

CHANGE HISTORY

A Correction to this paper has been published:
https://doi.org

The Retraction Note was updated to reflect reception of statements of disagreement from all authors.

This article has been retracted.Please see the Retraction Notice for more detail:
https://doi.org

References

[1] Rumgay H, Colombet M, Ramos da Cunha A, et al. Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022. CA Cancer J Clin. 2026;1-13. https://doi.org/10.3322/caac.70048.

[2] Collaborators GBDC. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025; 406(10512):1565-1586. https://doi.org/10.1016/S0140-6736(25)01635-6.

[3] Xue NN, Wang Y, Wang ZY, et al. Trends in immunotherapy for oral squamous cell carcinoma. Cell Oncol (Dordr). 2025; 48(5):1159-1179. https://doi.org/10.1007/s13402-025-01068-3.

[4] Cascardi E, Della Mura M, Sgarro N, et al. Chorus line in oral squamous cell carcinoma: how stromal and immune players orchestrate tumor progression (Review). Int J Mol Med. 2026; 57(4):90. https://doi.org/10.3892/ijmm.2026.5761.

[5] Zhou FY, Waterman DP, Ashton M, et al. Prolonged cell cycle arrest in response to DNA damage in yeast requires the maintenance of DNA damage signaling and the spindle assembly checkpoint. eLife. 2024; 13:RP94334. https://doi.org/10.7554/eLife.94334.

[6] Cecati M, Pozzi V, Pompei V, et al. Cisplatin as a xenobiotic agent: molecular mechanisms of actions and clinical applications in oncology. J Xenobiot. 2026; 16(1):9. https://doi.org/10.3390/jox16010009.

[7] Lin X, Wang F, Chen J, et al. N(6)-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil Med Res. 2022; 9(1):19. https://doi.org/10.1186/s40779-022-00378-z.

[8] Ren X, Chen H, Wang H, et al. Advances in the pharmacological effects and mechanisms of Nelumbo nucifera gaertn. Extract nuciferine. J Ethnopharmacol. 2024; 331:118262. https://doi.org/10.1016/j.jep.2024.118262.

[9] Bharathi PL, Huang CY, Hu RM, et al. An updated review on pharmacological properties of neferine-A bisbenzylisoquinoline alkaloid from Nelumbo nucifera. J Food Biochem. 2021; 45(12):e13986. https://doi.org/10.1111/jfbc.13986.

[10] Wang XJ, Li B, Gao JY, et al. The OGG1 Ser326Cys polymorphism: molecular mechanisms of disease susceptibility and precision medicine applications. Clin Epigenetics. 2025; 17(1):153. https://doi.org/10.1186/s13148-025-01978-x.

[11] Sekeres M, Lengle D, Abbey L, et al. Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cells. Biochim Biophys Acta Mol Cell Res. 2025; 1872(7):120018. https://doi.org/10.1016/j.bbamcr.2025.120018.

[12] Gohil D, Sarker AH, Roy R . Base excision repair: mechanisms and impact in biology, disease, and medicine. Int J Mol Sci. 2023; 24(18):14186. https://doi.org/10.3390/ijms241814186.

[13] Carter J, Hulse M, Sivakumar M, et al. PRMT5 inhibitors regulate DNA damage repair pathways in cancer cells and improve response to PARP inhibition and chemotherapies. Cancer Res Commun. 2023; 3(11):2233-2243. https://doi.org/10.1158/2767-9764.CRC-23-0070.

[14] Shire Z, Vakili MR, Morgan TDR, et al. Nanoencapsulation of novel inhibitors of PNKP for selective sensitization to ionizing radiation and irinotecan and induction of synthetic lethality. Mol Pharm. 2018; 15(6):2316-2326. https://doi.org/10.1021/acs.molpharmaceut.8b00169.

[15] Wang Y, Coulombe Y, Yueh WT, et al. PALB2 and 53BP1 govern post-resection homologous recombination DNA repair. Mol Cell. 2025; 85(15):2824-2838. https://doi.org/10.1016/j.molcel.2025.07.003.

[16] Okano T, Takata M, Fujita M, et al. Recent advances in understanding the molecular mechanisms of SLX4 recruitment in the replication stress response. DNA Repair (Amst). 2025; 156:103911. https://doi.org/10.1016/j.dnarep.2025.103911.

[17] Liu Z, Yan WW, Liu SH, et al. Regulatory network and targeted interventions for CCDC family in tumor pathogenesis. Cancer Lett. 2023; 565:216225. https://doi.org/10.1016/j.canlet.2023.216225.

[18] Wang J, Wu X, Dai W, et al. The CCDC43-ADRM1 axis regulated by YY1, promotes proliferation and metastasis of gastric cancer. Cancer Lett. 2020; 482:90-101. https://doi.org/10.1016/j.canlet.2020.03.026.

[19] Chen Y, Pei M, Li J, et al. Disruption of the CCDC43-FHL1 interaction triggers apoptosis in gastric cancer cells. Exp Cell Res. 2022; 415(1):113107. https://doi.org/10.1016/j.yexcr.2022.113107.

[20] Wang J, Liu G, Liu M, et al. The FOXK1-CCDC43 axis promotes the invasion and metastasis of colorectal cancer cells. Cell Physiol Biochem. 2018; 51(6):2547-2563. https://doi.org/10.1159/000495924.

[21] Lin Y, Chen X, Lin L, et al. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3beta/beta-catenin signaling. Cell Mol Biol Lett. 2024; 29(1):63. https://doi.org/10.1186/s11658-024-00583-9.

[22] Lin X, Liu J, Zou Y, et al. Xanthotoxol suppresses non-small cell lung cancer progression and might improve patients’ prognosis. Phytomedicine . 2022; 105:154364. https://doi.org/10.1016/j.phymed.2022.154364.

[23] Lin X, Chen D, Chu X, et al. Oxypalmatine regulates proliferation and apoptosis of breast cancer cells by inhibiting PI3K/AKT signaling and its efficacy against breast cancer organoids. Phytomedicine. 2023; 114:154752. https://doi.org/10.1016/j.phymed.2023.154752.

[24] Lin X, Lin T, Wang X, et al. Sesamol serves as a p53 stabilizer to relieve rheumatoid arthritis progression and inhibits the growth of synovial organoids. Phytomedicine. 2023; 121:155109. https://doi.org/10.1016/j.phymed.2023.155109.

[25] Lin X, Chen J, Tao C, et al. Osthole regulates N6-methyladenosine-modified TGM2 to inhibit the progression of rheumatoid arthritis and associated interstitial lung disease. Med Comm. 2023; 4(2):e219. https://doi.org/10.1002/mco2.219.

[26] Zhou Y, Wang L, Liu M, et al. Oral squamous cell carcinoma: insights into cellular heterogeneity, drug resistance, and evolutionary trajectories. Cell Biol Toxicol. 2025; 41(1):101. https://doi.org/10.1007/s10565-025-10048-0.

[27] Wang Z, Zhang H, Zhai Y, et al. Single-cell profiling reveals heterogeneity of primary and lymph node metastatic tumors and immune cell populations and discovers important prognostic significance of CCDC43 in oral squamous cell carcinoma. Front Immunol. 2022; 13:843322. https://doi.org/10.3389/fimmu.2022.843322.

[28] Ball NJ, Barnett SFH, Goult BT . Mechanically operated signalling scaffolds. Biochem Soc Trans. 2024; 52(2):517-527. https://doi.org/10.1042/BST20221194.

[29] Priyanka PP, Yenugu S . Coiled-coil domain-containing (CCDC) proteins: functional roles in general and male reproductive physiology. Reprod Sci. 2021; 28(10):2725-2734. https://doi.org/10.1007/s43032-021-00595-2.

[30] Shen H, Li H, Tang H. CCDC110 promotes the progression of hepatocellular carcinoma by activating the TGF-beta/SMAD signaling pathway through targeted regulation of TGFBR1. Cancer Cell Int. 2025; 25(1):183. https://doi.org/10.1186/s12935-025-03803-0.

[31] Boccard SG, Marand SV, Geraci S, et al. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Oncotarget. 2015; 6(30):29456-68. https://doi.org/10.18632/oncotarget.4909.

[32] Yates LA, Zhang X, Burgers PM . DNA damage and replication stress checkpoints. Annu Rev Biochem. 2025; 94(1):195-221. https://doi.org/10.1146/annurev-biochem-072324-031915.

[33] Morozko EL, Smith-Geater C, Monteys AM, et al. PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington’s disease. Proc Natl Acad Sci U S A. 2021; 118(4):e2021836118. https://doi.org/10.1073/pnas.2021836118.

[34] Hong SH, Nguyen T, Ongkingco JF, et al. From concepts to inhibitors: a blueprint for targeting protein-protein interactions. Chem Rev. 2025; 125(14):6819-6869. https://doi.org/10.1021/acs.chemrev.5c00046.

[35] Manan A, Baek E, Ilyas S, et al. Digital alchemy: the rise of machine and deep learning in small-molecule drug discovery. Int J Mol Sci. 2025; 26(14):6807. https://doi.org/10.3390/ijms26146807.

[36] Szalai TV, Peczka N, Sipos-Szabo L, et al. Ultrahigh-throughput virtual screening strategies against PPI targets: a case study of STAT inhibitors. J Chem Inf Model. 2025; 65(14):7734-7748. https://doi.org/10.1021/acs.jcim.5c00907.

[37] Xie B, Tian LW, Liu C, et al. Disruption of the eEF1A1/ARID3A/PKC-delta complex by Neferine inhibits macrophage glycolytic reprogramming in atherosclerosis. Adv Sci (Weinh). 2025; 12(15):e2416158. https://doi.org/10.1002/advs.202416158.

[38] Manogaran P, Somasundaram B, Viswanadha VP . Reversal of cisplatin resistance by neferine/isoliensinine and their combinatorial regimens with cisplatin-induced apoptosis in cisplatin-resistant colon cancer stem cells (CSCs). J Biochem Mol Toxicol. 2022; 36(3):e22967. https://doi.org/10.1002/jbt.22967.

[39] Li H, Ge H, Song X, et al. Neferine mitigates cisplatin-induced acute kidney injury in mice by regulating autophagy and apoptosis. Clin Exp Nephrol. 2023; 27(2):122-131. https://doi.org/10.1007/s10157-022-02292-z.

[40] Liu Y, Wang C, Liao Q, et al. Pharmacological potential and mechanisms of bisbenzylisoquinoline alkaloids from lotus seed embryos. Biomolecules. 2025; 15(10):1377. https://doi.org/10.3390/biom15101377.